# Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One® in Chinese Patients With Symptomatic Osteoarthritis of the Knee

> **NCT03190369** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 440 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **DEVICE:** Hylan G-F 20 (GZ402662/SAR402662)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03190369
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-21
- **Primary completion:** 2019-01-28
- **Final completion:** 2019-01-28
- **Target enrollment:** 440 (ACTUAL)
- **Last updated:** 2022-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03190369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03190369, "Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One® in Chinese Patients With Symptomatic Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03190369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*